Skip to content

SLN Mapping and ICG Dye for Vulvar Cancer

Sentinel Lymph Node Mapping and Detection With Indocyanine Green and Spy-Phi Handheld Camera Technology in Early-Stage Vulvar Cancer (PILOT)

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06035068
Enrollment
10
Registered
2023-09-13
Start date
2025-11-01
Completion date
2026-01-31
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulva Cancer

Brief summary

Doctors typically use blue dye to assist in locating and extracting lymph nodes for biopsy. However, this process can prove somewhat challenging for both patients and medical teams due to its need for extensive coordination and the assistance of a nuclear medicine team. Some studies have talked about using a different method to find these lymph nodes using a special dye called Indocyanine Green (ICG). This method involves shining a special camera on the skin. So far, no studies have directly compared the ICG method to the standard blue dye. The ICG camera could make things easier for patients and doctors, and more patients might choose to have their lymph nodes checked with this new method. The goal of our study is to see if using the ICG dye is just as good as the standard method of blue dye.

Interventions

DRUGIndocyanine green

Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.

Sponsors

Tufts Medical Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older * Patients with early-stage SCC (diameter \<4 cm) of the vulva without suspicious lymph nodes at palpation or imaging who are planned for surgery at Tufts Medical Center. * Patients with squamous cell carcinoma, depth of invasion \> 1mm * Patients with T1 or T2 tumors (FIGO staging) \< 4 cm, not encroaching in urethra or anus with clinically negative inguinofemoral lymph nodes * Localization and size of the tumor are such that perilesional injection of the tracers at three or four sites is possible * Preoperative imaging do not show enlarged (\<1.5 cm)/ suspicious nodes * Willing and able to give informed consent

Exclusion criteria

* Inoperable tumors and tumors with diameter \> 4 cm * Patients with inguinofemoral lymph nodes that are palpable on clinical exam suspicious for metastases or with cytologically proven inguinofemoral lymph node metastases * Radiologically enlarged (\>1.5 cm) inguinofemoral lymph nodes * Patients with multifocal tumors * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Detection Rate of SLNs using ICG Dye vs Blue Dye at Patient LevelData collection at time of surgery* Report the detection rate of SLNs using ICG dye for sentinel lymph node mapping. * Report the detection rate of SLNs using blue dye for sentinel lymph node mapping. * Compare the two detection rates using a chi-squared test or Fisher's exact test, depending on the sample size.
Clustered Analysis at the Hemi-Pelvis LevelData collection at time of surgery* Use generalized estimating equations (GEE) or mixed-effects logistic regression models to account for the clustering effect. * Include a random effect for each patient to address the correlation between SLNs within the same patient's hemi-pelvis. * Assess the significance of dye type using the Wald test or likelihood ratio test. * Report odds ratios, confidence intervals, and p-values for the effect of dye type on SLN detection.
3. Difference in SLNs Detected in Blue vs Green Dye when Data is Clustered at Hemi-Pelvis LevelData collection at time of surgery* Report the proportion of SLNs detected using blue dye in each hemi-pelvis. * Report the proportion of SLNs detected using ICG dye in each hemi-pelvis. * Use a paired t-test or Mcnemar's test to compare the proportions within each hemi-pelvis. * Account for the clustering effect by using mixed-effects models

Secondary

MeasureTime frameDescription
Sensitivity, Specificity, and Negative Predictive Value of ICG Dye vs Standard Blue DyeData collection at time of surgery* Create a 2x2 contingency table for sensitivity, specificity, and negative predictive value. * Sensitivity = (True Positives) / (True Positives + False Negatives). * Specificity = (True Negatives) / (True Negatives + False Positives). * Negative Predictive Value = (True Negatives) / (True Negatives + False Negatives).

Countries

United States

Contacts

Primary ContactRafael Gonzalez, MD
rafael.gonzalez@tuftsmedicine.org617-636-6058
Backup ContactKatina Robison, MD
katina.robison@tuftsmedicine.org

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026